lncRNA CYTOR promotes tamoxifen resistance in breast cancer cells via sponging miR‑125a‑5p

Liu,Yungyong; Li,Mengdan; Yu,Huihui; Piao,Haozhe

doi:10.3892/ijmm.2019.4428

lncRNA CYTOR promotes tamoxifen resistance in breast cancer cells via sponging miR‑125a‑5p

Authors:
- Yungyong Liu
- Mengdan Li
- Huihui Yu
- Haozhe Piao
View Affiliations

Affiliations: Department of Cancer Prevention and Control, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, Shenyang, Liaoning 110042, P.R. China, Department of Neurosurgery, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, Shenyang, Liaoning 110042, P.R. China
Published online on: December 16, 2019 https://doi.org/10.3892/ijmm.2019.4428
Pages: 497-509
Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Development of resistance to endocrine therapy, such as tamoxifen, remains a tricky clinical problem during the treatment of breast cancer. Accumulating evidence suggested that dysregulation of long noncoding (lnc_RNAs contributes to the development of tamoxifen resistance. In the current study, via screening, cytoskeleton regulator RNA (CYTOR) was identified as the most significantly elevated lncRNA in the established tamoxifen resistant MCF7 cell lines (MCF7/TAM1 and MCF7/TAM2) compared with the parental MCF7 cells (MCF7‑P). The CCK‑8 assay indicated that silencing of CYTOR increased the sensitivity of MCF7/TAM1 and MCF7/TAM2 to tamoxifen treatment. Using bioinformatic analysis, it was predicted that microRNA (miR)‑125a‑5p might bind to CYTOR and the expression of miR‑125a‑5p was negatively correlated with CYTOR in the tumor tissues of breast cancer. In addition, RT‑qPCR and dual luciferase assays validated that CYTOR directly repressed miR‑125a‑5p expression in breast cancer cells. Through regulation of miR‑125a‑5p, CYTOR elevated serum response factor (SRF) expression and activated Hippo and mitogen associated protein kinase signaling pathways to promote breast cancer cell survival upon tamoxifen treatment. In the collected tumor tissues of breast cancer in the present study, high expression of CYTOR was detected in tissues from patients with no response to tamoxifen compared with those from patients who were not treated with tamoxifen. A positive correlation between CYTOR and SRF mRNA expression was observed in tissues collected from patients with breast cancer. In conclusion, the results of the present study demonstrated a pivotal role of CYTOR in mediating tamoxifen resistance in breast cancer.

View Figures

View References

1	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
2	Liu J, Li J, Wang H, Wang Y, He Q, Xia X, Hu ZY and Ouyang Q: Clinical and genetic risk factors for Fulvestrant treatment in post-menopause ER-positive advanced breast cancer patients. J Transl Med. 17:272019. View Article : Google Scholar : PubMed/NCBI
3	Doisneau-Sixou SF, Sergio CM, Carroll JS, Hui R, Musgrove EA and Sutherland RL: Estrogen and antiestrogen regulation of cell cycle progression in breast cancer cells. Endocr Relat Cancer. 10:179–186. 2003. View Article : Google Scholar : PubMed/NCBI
4	Clarke R, Tyson JJ and Dixon JM: Endocrine resistance in breast cancer-An overview and update. Mol Cell Endocrinol. 418(Pt 3): 220–234. 2015. View Article : Google Scholar :
5	Shang Y, Hu X, DiRenzo J, Lazar MA and Brown M: Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. Cell. 103:843–852. 2000. View Article : Google Scholar
6	Roop RP and Ma CX: Endocrine resistance in breast cancer: Molecular pathways and rational development of targeted therapies. Future Oncol. 8:273–292. 2012. View Article : Google Scholar : PubMed/NCBI
7	Giuliano M, Schifp R, Osborne CK and Trivedi MV: Biological mechanisms and clinical implications of endocrine resistance in breast cancer. Breast. 20(Suppl 3): S42–S49. 2011. View Article : Google Scholar : PubMed/NCBI
8	Piggott L, Silva A, Robinson T, Santiago-Gómez A, Simões BM, Becker M, Fichtner I, Andera L, Young P, Morris C, et al: Acquired resistance of ER-Positive breast cancer to endocrine treatment confers an adaptive sensitivity to TRAIL through posttranslational downregulation of c-FLIP. Clin Cancer Res. 24:2452–2463. 2018. View Article : Google Scholar : PubMed/NCBI
9	Anurag M, Punturi N, Hoog J, Bainbridge MN, Ellis MJ and Haricharan S: Comprehensive profiling of DNA repair defects in breast cancer identifies a novel class of endocrine therapy resistance drivers. Clin Cancer Res. 24:4887–4899. 2018. View Article : Google Scholar : PubMed/NCBI
10	Ponting CP, Oliver PL and Reik W: Evolution and functions of long noncoding RNAs. Cell. 136:629–641. 2009. View Article : Google Scholar : PubMed/NCBI
11	Bhan A, Soleimani M and Mandal SS: Long noncoding RNA and cancer: A new paradigm. Cancer Res. 77:3965–3981. 2017. View Article : Google Scholar : PubMed/NCBI
12	Xu S, Kong D, Chen Q, Ping Y and Pang D: Oncogenic long noncoding RNA landscape in breast cancer. Mol Cancer. 16:1292017. View Article : Google Scholar : PubMed/NCBI
13	Sun M, Nie F, Wang Y, Zhang Z, Hou J, He D, Xie M, Xu L, De W, Wang Z and Wang J: LncRNA HOXA11-AS promotes proliferation and invasion of gastric cancer by scaffolding the chromatin modification factors PRC2, LSD1, and DNMT1. Cancer Res. 76:6299–6310. 2016. View Article : Google Scholar : PubMed/NCBI
14	Wei GH and Wang X: lncRNA MEG3 inhibit proliferation and metastasis of gastric cancer via p53 signaling pathway. Eur Rev Med Pharmacol Sci. 21:3850–3856. 2017.PubMed/NCBI
15	Zhao J, Liu Y, Zhang W, Zhou Z, Wu J, Cui P, Zhang Y and Huang G: Long non-coding RNA Linc00152 is involved in cell cycle arrest, apoptosis, epithelial to mesenchymal transition, cell migration and invasion in gastric cancer. Cell Cycle. 14:3112–3123. 2015. View Article : Google Scholar : PubMed/NCBI
16	Cai Q, Wang ZQ, Wang SH, Li C, Zhu ZG, Quan ZW and Zhang WJ: Upregulation of long non-coding RNA LINC00152 by SP1 contributes to gallbladder cancer cell growth and tumor metastasis via PI3K/AKT pathway. Am J Transl Res. 8:4068–4081. 2016.PubMed/NCBI
17	Wang X, Yu H, Sun W, Kong J, Zhang L, Tang J, Wang J, Xu E, Lai M and Zhang H: The long non-coding RNA CYTOR drives colorectal cancer progression by interacting with NCL and Sam68. Mol Cancer. 17:1102018. View Article : Google Scholar : PubMed/NCBI
18	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar
19	Fan W, Chang J and Fu P: Endocrine therapy resistance in breast cancer: Current status, possible mechanisms and overcoming strategies. Future Med Chem. 7:1511–1519. 2015. View Article : Google Scholar : PubMed/NCBI
20	Foxo3a re-expression overcomes tamoxifen resistance in breast cancer. J Biol Regul Homeost Agents. 32(4 Suppl 1): S432018.
21	Gao A, Sun T, Ma G, Cao J, Hu Q, Chen L, Wang Y, Wang Q, Sun J, Wu R, et al: LEM4 confers tamoxifen resistance to breast cancer cells by activating cyclin D-CDK4/6-Rb and ERα pathway. Nat Commun. 9:41802018. View Article : Google Scholar
22	Shi YF, Lu H and Wang HB: Downregulated lncRNA ADAMTS9-AS2 in breast cancer enhances tamoxifen resistance by activating microRNA-130a-5p. Eur Rev Med Pharmacol Sci. 23:1563–1573. 2019.PubMed/NCBI
23	Xu CG, Yang MF, Ren YQ, Wu CH and Wang LQ: Exosomes mediated transfer of lncRNA UCA1 results in increased tamoxifen resistance in breast cancer cells. Eur Rev Med Pharmacol Sci. 20:4362–4368. 2016.PubMed/NCBI
24	Salmena L, Poliseno L, Tay Y, Kats L and Pandolfi PP: A ceRNA hypothesis: The rosetta stone of a hidden RNA language? Cell. 146:353–358. 2011. View Article : Google Scholar : PubMed/NCBI
25	Zhang J and Li W: Long noncoding RNA CYTOR sponges miR-195 to modulate proliferation, migration, invasion and radiosensitivity in nonsmall cell lung cancer cells. Biosci Rep. 38:BSR201815992018. View Article : Google Scholar : PubMed/NCBI
26	Yuan Y, Wang J, Chen Q, Wu Q, Deng W, Zhou H and Shen D: Long non-coding RNA cytoskeleton regulator RNA (CYTOR) modulates pathological cardiac hypertrophy through miR-155-mediated IKKi signaling. Biochim Biophys Acta Mol Basis Dis. 1865:1421–1427. 2019. View Article : Google Scholar : PubMed/NCBI
27	Van Grembergen O, Bizet M, de Bony EJ, Calonne E, Putmans P, Brohée S, Olsen C, Guo M, Bontempi G, Sotiriou C, et al: Portraying breast cancers with long noncoding RNAs. Sci Adv. 2:e16002202016. View Article : Google Scholar : PubMed/NCBI
28	Shen X, Zhong J, Yu P, Zhao Q and Huang T: YY1-regulated LINC00152 promotes triple negative breast cancer progression by affecting on stability of PTEN protein. Biochem Biophys Res Commun. 509:448–454. 2019. View Article : Google Scholar
29	Yan L, Yu MC, Gao GL, Liang HW, Zhou XY, Zhu ZT, Zhang CY, Wang YB and Chen X: MiR-125a-5p functions as a tumour suppressor in breast cancer by downregulating BAP1. J Cell Biochem. 119:8773–8783. 2018. View Article : Google Scholar : PubMed/NCBI
30	Sun Y, Liu X, Zhang Q, Mao X, Feng L, Su P, Chen H, Guo Y and Jin F: Oncogenic potential of TSTA3 in breast cancer and its regulation by the tumor suppressors miR-125a-5p and miR-125b. Tumour Biol. 37:4963–4972. 2016. View Article : Google Scholar
31	Huang WK, Akçakaya P, Gangaev A, Lee L, Zeljic K, Hajeri P, Berglund E, Ghaderi M, Åhlén J, Bränström R, et al: miR-125a-5p regulation increases phosphorylation of FAK that contributes to imatinib resistance in gastrointestinal stromal tumors. Exp Cell Res. 371:287–296. 2018. View Article : Google Scholar : PubMed/NCBI
32	Hu X, Jiang H and Jiang X: Downregulation of lncRNA ANRIL inhibits proliferation, induces apoptosis, and enhances radiosensitivity in nasopharyngeal carcinoma cells through regulating miR-125a. Cancer Biol Ther. 18:331–338. 2017. View Article : Google Scholar : PubMed/NCBI
33	Zhang Y, Liu Y and Xu X: Knockdown of LncRNA-UCA1 suppresses chemoresistance of pediatric AML by inhibiting glycolysis through the microRNA-125a/hexokinase 2 pathway. J Cell Biochem. 119:6296–6308. 2018. View Article : Google Scholar : PubMed/NCBI
34	Treisman R: Identification of a protein-binding site that mediates transcriptional response of the c-fos gene to serum factors. Cell. 46:567–574. 1986. View Article : Google Scholar : PubMed/NCBI
35	Miralles F, Posern G, Zaromytidou AI and Treisman R: Actin dynamics control SRF activity by regulation of its coactivator MAL. Cell. 113:329–342. 2003. View Article : Google Scholar : PubMed/NCBI
36	Kim T, Yang SJ, Hwang D, Song J, Kim M, Kyum Kim S, Kang K, Ahn J, Lee D, Kim MY, et al: A basal-like breast cancer-specific role for SRF-IL6 in YAP-induced cancer stemness. Nat Commun. 6:101862015. View Article : Google Scholar : PubMed/NCBI
37	Liu CY, Chan SW, Guo F, Toloczko A, Cui L and Hong W: MRTF/SRF dependent transcriptional regulation of TAZ in breast cancer cells. Oncotarget. 7:13706–13716. 2016.PubMed/NCBI
38	Liu J, Li J, Li P, Jiang Y, Chen H, Wang R, Cao F and Liu P: DLG5 suppresses breast cancer stem cell-like characteristics to restore tamoxifen sensitivity by inhibiting TAZ expression. J Cell Mol Med. 23:512–521. 2019. View Article : Google Scholar